Philip T. Cagle, Timothy C. Allen, Eric H. Bernicker, Yimin Ge, Abida Haque, and Roberto Barrios (2016) Impact of Recent Developments in Lung Cancer on the Practice of Pathology. Archives of Pathology & Laboratory Medicine: April 2016, Vol. 140, No. 4, pp. 322-325.

CONTRIBUTIONS FROM THE PULMONARY PATHOLOGY SOCIETY, PART II

Impact of Recent Developments in Lung Cancer on the Practice of Pathology

Philip T. Cagle , MD; Timothy C. Allen , MD, JD; Eric H. Bernicker , MD; Yimin Ge , MD; Abida Haque , MD; Roberto Barrios , MD

From the Department of Pathology and Genomic Medicine (Drs Cagle, Ge, Haque, and Barrios)

and Houston Methodist Cancer Center (Dr Bernicker),

Houston Methodist Hospital, Houston, Texas; and the Department of Pathology and Laboratory Medicine, University of Texas Medical Branch, Houston (Dr Allen).

"Even with these caveats, the participation of surgical pathologists and cytopathologists in biomarker testing for lung cancer, while already crucial, becomes even more intimate when the test is directly interpreted by the pathologist using tools of routine practice and is performed in the pathologist-managed histology laboratory. Current requirements of the FDA will likely be modified in the future by pressures from the patients, their oncologists, and their advocates. The potential for impact of biomarker testing with IHC on the practice of pathology is extremely large, given the number of patients receiving a diagnosis of lung cancer."